News
US FDA approves HIV prevention drug: Why is this a breakthrough?
A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States’ Food and Drug Administration. With better compliance expected — instead of daily pills on a shot every two months that people have to take at the moment — it is one of the most anticipated developments in the field of HIV prevention.
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a ...
The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.
The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...
The drug, lamivudine, appears to improve vision that’s being threatened by diabetic macular edema (DME), an eye condition in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback